Erasca Q3 2022 Earnings Report
Key Takeaways
Erasca reported positive preliminary monotherapy data for ERAS-007 and ERAS-601, signed CTCSAs with Eli Lilly and Pfizer, and a strategic R&D collaboration with MD Anderson. The company's cash, cash equivalents, and marketable securities totaled $365 million.
Reported promising preliminary Phase 1/1b data for ERAS-007 and ERAS-601 in advanced solid tumors.
Signed CTCSAs with Eli Lilly to supply cetuximab in combination with ERAS-601 and with Pfizer to supply palbociclib in combination with ERAS-007.
Entered a strategic R&D collaboration with MD Anderson.
Expects to file an IND for CNS-penetrant KRAS G12C inhibitor ERAS-3490 before year-end.
Erasca
Erasca
Forward Guidance
Erasca anticipates filing an IND for ERAS-3490 in KRAS G12C mutant NSCLC before year-end. In the first half of 2023, they expect to initiate a dose escalation trial for ERAS-007 in combination with ERAS-601 and report combination data for ERAS-007 in gastrointestinal malignancies and ERAS-601 in triple wildtype CRC.
Positive Outlook
- IND filing anticipated in the second half of 2022 for ERAS-3490
- Initiation of a Phase 1b dose escalation trial for ERAS-007 in combination with ERAS-601 anticipated in the first half of 2023
- Initial Phase 1b combination data anticipated in the first half of 2023 for HERKULES-3
- Initial Phase 1b combination data in triple wildtype CRC anticipated in the first half of 2023 for FLAGSHP-1
- Initial Phase 1b combination data anticipated in 2023 for HERKULES-2